TGF-beta induced RBL2 expression in renal cancer cells by down-regulating miR-93

Clinical and Translational Oncology

Volumn 16, Issue 11, 2014, Pages 986-992

  Shi, J ^a   Zhuang, Y ^a   Liu, X K ^b   Zhang, Y X ^b   Zhang, Y ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle regulation; miR 93; Proliferation; RBL2; Renal cancer; TGF beta

Indexed keywords

MICRORNA; MICRORNA 93; PROTEIN P130; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; MIRN93 MICRORNA, HUMAN; RBL2 PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; KIDNEY CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA PROCESSING; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KIDNEY TUMOR; METABOLISM; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; RETINOBLASTOMA-LIKE PROTEIN P130; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84919623744     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1185-7     Document Type: Article

References (23)

1. Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab. 1998;24:111–9.
2. Brizzi MF, Dentelli P, Rosso A, Calvi C, Gambino R, Cassader M, et al. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. FASEB J. 2004;18:1249–51.
3. Wolf G, Schroeder R, Zahner G, Stahl RA, Shankland SJ. High glucose-induced hypertrophy of mesangial cells requires p27(Kip1), an inhibitor of cyclin-dependent kinases. Am J Pathol. 2001;158:1091–100.
4. Galliher AJ, Neil JR, Schiemann WP. Role of transforming growth factor beta in cancer progression. Future Oncol. 2006;2:743–63.
5. Sengupta S, Kundu S, Bhattacharyya A. Attenuation of Smad2 activity shows resistance to TGF-β signalling in mammary adenocarcinoma (MCF-7) cells. Cell Biol Int. 2013;37:449–57.
6. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci. 2012;8:964–78.
7. Drabsch Y, ten Dijke P. TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012;31:553–68.
8. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350–3.
9. Ramp U, Jaquet K, Reinecke P, Nitsch T, Gabbert HE, Gerharz CD. Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest. 1997;76:739–49.
10. Shang D, Liu Y, Yang P, Chen Y, Tian Y. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel–Lindau tumor suppressor. Urology. 2012;79:966.e1–7.
11. Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 2011;286:8655–65.
12. Ewen ME. p53-dependent repression of cdk4 synthesis in transforming growth factor-beta-induced G1 cell cycle arrest. J Lab Clin Med. 1996;128:355–60.
13. Choi HH, Jong HS, Hyun Song S, You Kim T, Kyeong Kim N, Bang YJ. p130 mediates TGF-beta-induced cell-cycle arrest in Rb mutant HT-3 cells. Gynecol Oncol. 2002;86:184–9.
14. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6:376–85.
15. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13:272–86.
16. Ravitz MJ, Wenner CE. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res. 1997;71:165–207.
17. Lewis BP, Burge CP, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.
18. Liang LH, He XH. Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy. Acta Pharmacol Sin. 2011;32:1311–20.
19. Redova M, Svoboda M, Slaby O. MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun. 2011;405:153–6.
20. Schaefer A, Stephan C, Busch J, Yousef GM, Jung K. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol. 2010;7:286–97.
21. Hata A, Davis BN. Control of microRNA biogenesis by TGFbeta signaling pathway—a novel role of Smads in the nucleus. Cytokine Growth Factor Rev. 2009;20:517–21.
22. Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008;68:8191–4.
23. Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, et al. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer. 2008;123:972–8.